Clinical endocannabinoid deficiency may be associated with numerous gastrointestinal problems including colitis, inflammatory bowel disease (IBD), Crohn’s disease, and other inflammatory disorders of the gut.
- Saltzman, John, R. Burden and costs of gastrointestinal disease in the U.S. Gastroenterology: NEJM Journal Watch. October, 2018. (https://pubmed.ncbi.nlm.nih.gov/11984534/)
- Russo, Ethan, B. Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabinoid and Cannabinoid Research. 1(1): 154-165. 2016. (https://pubmed.ncbi.nlm.nih.gov/28861491/)
- De Filippis, D. Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. Plos One. 6(12): 1-8. 2011. (https://pubmed.ncbi.nlm.nih.gov/22163000/)
- Izzo, A.A., and Sharkey, K.A. Cannabinoids and the gut: new developments and emerging concepts. Pharmacology and Therapeutics. 126(1): 21-38. 2010. (https://pubmed.ncbi.nlm.nih.gov/20117132/)
- Esposito, G. et al. Cannabidiol in inflammatory bowel diseases: a brief overview. Phytotherapy Research. 27(5): 633-636. 2012. (https://pubmed.ncbi.nlm.nih.gov/22815234/)
- Schicho, R. and Martin Storr. Cannabis finds its way into treatment of Crohn’s disease. Pharmacology. 93(0): 1-3. 2014. (https://pubmed.ncbi.nlm.nih.gov/24356243/)
- Borrelli, F, et al. Cannbidiol, a safe and non-psychotropic ingredient of the marijuana plant cannabis sativa, is a protective in a murine model of colitis. Journal of Molecular Medicine Berlin. 87(11): 1111-1121. 2009. (https://pubmed.ncbi.nlm.nih.gov/19690824/)
- Smith, Gregory, L. Cannabidiol (CBD). What you need to know. 2017.